Novartis Just Bet $1.9 Billion on a Company That Doesn't Exist Yet
Novartis just agreed to pay up to $1.9 billion to a one-year-old spinout with zero clinical data. The catch: Antares Therapeutics might hold the key to drugging cancer targets that have stumped the entire industry for decades.
The Check Cleared Before the Lab Coat Was On
Imagine paying nearly $2 billion for a restaurant that hasn't opened yet, doesn't have a menu, and the chef just finished culinary school. That's roughly what Novartis just did in biotech terms.
On Thursday, the Swiss pharma giant signed a deal with Antares Therapeutics worth up to $1.9 billion to discover small-molecule drugs against cancer targets that nobody has been able to drug before. Antares gets $105 million upfront, with up to $1.8 billion more in option fees and milestones if things go well. The kicker? Antares is a discovery-stage company. Its most advanced program hasn't even entered human testing yet.
So why is Novartis writing a nine-figure check for science that's still mostly on whiteboards?
Because the targets Antares is chasing represent one of oncology's biggest unsolved problems. And Novartis isn't the only one who thinks this team can crack it.
The 80% Problem
Here's a stat that should make you uncomfortable: roughly 80% of cancer-driving proteins are still considered "undruggable" by traditional methods. These aren't obscure proteins hiding in the corner of some biology textbook. They're the heavy hitters, the ones scientists know are fueling tumors. Proteins like KRAS, MYC, p53, and a whole family of transcription factors (proteins that control which genes get turned on and off).
The problem isn't that we don't know they matter. It's that they're shaped wrong. Traditional drugs work like keys fitting into locks; they slide into grooves and pockets on a protein's surface to block its activity. But many of these cancer-driving proteins are essentially smooth spheres. No grooves. No pockets. No place for a drug to grab hold. It's like trying to hang a coat on a bowling ball.
That's the challenge Antares was built to solve.
Born From a $2.5 Billion Breakup
Antares didn't appear out of thin air. Its origin story reads like a biotech soap opera.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The company is a spinout from Scorpion Therapeutics, a precision oncology startup founded in 2020 by a murderer's row of cancer scientists, including Keith Flaherty (who also co-founded Loxo Oncology, later acquired by Eli Lilly for about $8 billion). Scorpion built a platform combining chemical proteomics, machine learning, and medicinal chemistry to find hidden binding sites on proteins everyone else had given up on.
Their crown jewel was STX-478, a mutant-selective PI3Kα inhibitor for breast cancer and solid tumors. In January 2025, Eli Lilly swooped in and bought that program for up to $2.5 billion.
But Lilly only wanted the one drug. The rest of Scorpion's team, platform, and pipeline needed a home. So the company's existing shareholders did something clever: they spun out everything Lilly didn't buy into a new entity. That entity launched in June 2025 as Antares Therapeutics, backed by a $177 million Series A from investors including Omega Funds, Atlas Venture, and Lightspeed Venture Partners.
Same team. Same platform. Same CEO, Adam Friedman. New name. New targets. And now, a very large new partner in Novartis.
What Antares Actually Does
If undruggable proteins are bowling balls, Antares claims it can find the tiny scratches and dents where a drug might stick.
The company uses proprietary chemical proteomics (a fancy way of saying they chemically probe the entire protein landscape of a cell) to identify hidden, transient binding pockets that don't show up on static images. Think of it like the difference between a photograph and a video: a still image of a protein might look smooth, but in motion, little crevices open and close. Antares hunts for those moments.
They pair this with machine learning to predict which of those fleeting pockets are actually useful for drug design, then hand the best candidates to medicinal chemists who design small molecules to exploit them. The whole system is built to turn "impossible" targets into real drug programs.
Antares has also inherited programs from a 2022 collaboration between Scorpion and AstraZeneca focused on transcription factors, one of the most notoriously undruggable protein classes in all of biology. Board member Sir Menelas Pangalos has highlighted the company's work in "unlocking the therapeutic potential of targets long seen as important but undruggable, particularly transcription factors."
Why Novartis Is Paying Up
The deal structure tells you a lot about how Novartis is thinking. This isn't an acquisition. It's more like a fishing license with premium bait.
Antares will lead the research across multiple undisclosed cancer targets. Novartis gets to watch the science unfold and then exercise options on the programs it likes, securing global rights to develop and commercialize those drugs. If everything hits (a big "if" at this stage), the total payout could reach $1.9 billion, including tiered royalties in the low double-digit range.
For Novartis, this fits a clear strategic pattern. In recent years the company has been layering external innovation onto its oncology pipeline through both acquisitions (MorphoSys, Anthos Therapeutics, Tourmaline Bio) and research collaborations. The Antares deal gives Novartis access to a cutting-edge platform without the commitment of a full buyout. It's essentially buying optionality on the future of cancer drug discovery.
Deutsche Bank apparently agrees with the logic, reiterating a Buy rating on Novartis after the announcement. The stock barely moved, hovering near its 52-week high. Wall Street's read: this is a smart long-term bet, not a short-term catalyst.
The Bigger Picture
Antares isn't operating in a vacuum. The race to drug "undruggable" targets is one of the hottest themes in biotech right now, and the competitive landscape is crowded with different technological approaches.
Targeted protein degradation (using molecules called PROTACs or molecular glues to tag unwanted proteins for destruction rather than blocking them) has over 50 candidates in clinical trials. Covalent chemistry platforms are mapping druggable hotspots across the entire proteome. AI-powered drug design companies are predicting protein structures and generating molecules computationally.
Each approach has strengths and trade-offs. What makes Antares interesting is the validation baked into its lineage. Scorpion's platform already produced STX-478, which was compelling enough for Lilly to pay $2.5 billion. That's not a guarantee the platform will work on harder targets, but it's a stronger proof point than most discovery-stage companies can offer.
Antares expects its first program to enter clinical trials in 2026, with multiple additional programs in preclinical development. The clock is ticking on whether the science can deliver what the deal terms promise.
The Bottom Line
A $1.9 billion deal for a one-year-old spinout with no clinical data sounds wild. And honestly, it kind of is. But the math makes sense when you consider that the targets Antares is pursuing represent some of the largest unmet needs in oncology, the team already built one platform good enough for a $2.5 billion exit, and Novartis is paying mostly in milestones that only trigger if the science works.
Novartis isn't betting $1.9 billion on Antares. It's betting $105 million on the chance that Antares cracks the code, with $1.8 billion more on the table if they actually do. That's not reckless. That's the new economics of going after cancer's hardest problems.
Deals & M&A5 min read
UCB Just Bet $1.15 Billion That Brain Cells Can Stop Seizures
UCB is spending up to $1.15 billion on Neurona Therapeutics and its lab-grown brain cell therapy for drug-resistant epilepsy. The early clinical data is stunning, but the real test is just getting started.
